Glycaemic Control and Hypoglycaemia in Children, Adolescents and Young Adults with Unstable Type 1 Diabetes Mellitus Treated with Insulin Glargine or Intermediate-acting Insulin
| العنوان: | Glycaemic Control and Hypoglycaemia in Children, Adolescents and Young Adults with Unstable Type 1 Diabetes Mellitus Treated with Insulin Glargine or Intermediate-acting Insulin |
|---|---|
| المؤلفون: | Jilrgen Herwig, Hans Bohles, Gabriele Scholl-Schilling |
| المصدر: | Journal of Pediatric Endocrinology and Metabolism. 20 |
| بيانات النشر: | Walter de Gruyter GmbH, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, Adolescent, Endocrinology, Diabetes and Metabolism, Insulin, Isophane, Insulin Glargine, NPH insulin, Hemoglobins, Endocrinology, Quality of life, Unstable type 1 diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Young adult, Child, Glycated Hemoglobin, Type 1 diabetes, Dose-Response Relationship, Drug, Insulin glargine, business.industry, Incidence, Incidence (epidemiology), medicine.disease, Hypoglycemia, Insulin, Long-Acting, Diabetes Mellitus, Type 1, Child, Preschool, Pediatrics, Perinatology and Child Health, Quality of Life, Early adolescents, Female, business, medicine.drug |
| الوصف: | In this open study of clinical practice, 142 paediatric patients with type 1 diabetes mellitus (>1 year duration), stratified by age, received prandial insulin (regular or lispro) and either once daily insulin glargine (GLAR; n=74), titrated to target fasting blood glucose (FBG) levels 4.4-7.8 mmol/l, or NPH/semilente insulin (NPH insulin, administered once, twice or three times daily; n=68), titrated to target FBG 4.4-8.9 mmol/l. Both groups were treated for 20 +/- 10 months. HbA(1c) significantly increased in GLAR (7.3 +/- 1.0% to 7.6 +/- 1.1%; p = 0.003) and NPH/semilente insulin (7.7 +/- 1.6% to 8.3 +/- 1.5%; p = 0.0001) treated patients. The incidence of symptomatic hypoglycaemia was comparable between GLAR versus NPH/semilente insulin at endpoint (2.19 vs. 1.94 episodes/week); however, the overall incidence of severe hypoglycaemia was significantly lower with GLAR versus NPH/semilente insulin (0.14 vs. 0.73 events/patient-year; p = 0.002). The daily insulin dose was similar between the treatment groups; however, perceived quality of life (QoL) was better with GLAR. GLAR is associated with equivalent glycaemic control, less severe hypoglycaemia and improved QoL compared with NPH/semilente insulin. |
| تدمد: | 2191-0251 0334-018X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c236c86ccf2316d66741d26f34df79ecTest https://doi.org/10.1515/jpem.2007.20.4.517Test |
| رقم الانضمام: | edsair.doi.dedup.....c236c86ccf2316d66741d26f34df79ec |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21910251 0334018X |
|---|